# Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer

> **NCT01051362** · PHASE2 · UNKNOWN · sponsor: **The First Affiliated Hospital of Guangzhou Medical University** · enrollment: 48 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** PLD and Carboplatin

## Key facts

- **NCT ID:** NCT01051362
- **Lead sponsor:** The First Affiliated Hospital of Guangzhou Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2006-02
- **Primary completion:** 2011-02
- **Final completion:** 2011-11
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2010-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051362, "Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01051362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*